Jim Mullen scours pri­vate eq­ui­ty deals amid biotech win­ter; Ex-Ab­b­Vie med­ical chief suc­ceeds Brig­gs Mor­ri­son at Syn­dax

Jim Mullen is in, by his count, his third or fourth “long, cold win­ter in biotech in­vest­ing.” But that’s not stop­ping the ex-Bio­gen CEO from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.